MA41943A - Polypeptides ciblant une fusion du vih - Google Patents

Polypeptides ciblant une fusion du vih

Info

Publication number
MA41943A
MA41943A MA041943A MA41943A MA41943A MA 41943 A MA41943 A MA 41943A MA 041943 A MA041943 A MA 041943A MA 41943 A MA41943 A MA 41943A MA 41943 A MA41943 A MA 41943A
Authority
MA
Morocco
Prior art keywords
fusion polypeptides
hiv fusion
hiv
polypeptides
fusion
Prior art date
Application number
MA041943A
Other languages
English (en)
Inventor
Jonathan Davis
Mark R Krystal
David L Wensel
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA41943A publication Critical patent/MA41943A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
MA041943A 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih MA41943A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US201562257474P 2015-11-19 2015-11-19

Publications (1)

Publication Number Publication Date
MA41943A true MA41943A (fr) 2018-02-28

Family

ID=55809237

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056222A MA56222A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih
MA041943A MA41943A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056222A MA56222A (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih

Country Status (25)

Country Link
US (2) US10407490B2 (fr)
EP (2) EP3985020A1 (fr)
JP (3) JP6894846B2 (fr)
KR (1) KR20170138558A (fr)
CN (1) CN107922474A (fr)
AU (2) AU2016252008B2 (fr)
BR (1) BR112017022790A2 (fr)
CA (1) CA2983276A1 (fr)
CL (1) CL2017002687A1 (fr)
CO (1) CO2017011583A2 (fr)
CR (1) CR20170482A (fr)
DO (1) DOP2017000246A (fr)
EA (1) EA035332B1 (fr)
ES (1) ES2884267T3 (fr)
HK (1) HK1243432A1 (fr)
IL (1) IL255122A0 (fr)
MA (2) MA56222A (fr)
MX (1) MX2017013687A (fr)
PE (1) PE20180162A1 (fr)
PH (1) PH12017501914A1 (fr)
PT (1) PT3286212T (fr)
SG (1) SG11201708441RA (fr)
TW (1) TW201643185A (fr)
UY (1) UY36650A (fr)
WO (1) WO2016171980A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
WO2019123262A1 (fr) 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Polypeptides de liaison à un antigène
CN108997482A (zh) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (fr) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions et procédés pour le traitement du virus de l'immunodéficience humaine
CN117980465A (zh) * 2021-08-30 2024-05-03 康霖生物科技(杭州)有限公司 一种用于艾滋病病毒感染基因治疗的基因序列构建体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
KR100566859B1 (ko) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Rna-단백질 융합물을 이용한 단백질의 선별
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001043779A2 (fr) * 1999-12-16 2001-06-21 Tanox, Inc. Conjugues anti-hiv1 pour le traitement du vih
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2416219C (fr) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060121480A1 (en) * 2002-09-27 2006-06-08 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
EP1729795B1 (fr) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
EA201000979A1 (ru) 2007-12-27 2011-02-28 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2516459A1 (fr) 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Molécules bivalentes destinées à inhiber l'entrée du vih
CA2796338C (fr) 2010-04-13 2020-03-24 Bristol-Myers Squibb Company Proteines a domaine de squelette base sur la fibronectine qui se lient a pcsk9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN102939538A (zh) * 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
EP2655411A1 (fr) 2010-12-22 2013-10-30 Bristol-Myers Squibb Company Protéines à domaine échafaudage à base de fibronectine qui se lient à l'il-23
US9880151B2 (en) 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
BR112014007469B1 (pt) 2011-09-27 2022-06-14 Janssen Biotech, Inc Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína
WO2014120891A2 (fr) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine
WO2014165093A2 (fr) * 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
CL2017002687A1 (es) 2018-04-20
JP2018516247A (ja) 2018-06-21
PE20180162A1 (es) 2018-01-18
PT3286212T (pt) 2021-08-24
US11155602B2 (en) 2021-10-26
WO2016171980A1 (fr) 2016-10-27
MA56222A (fr) 2022-04-20
HK1243432A1 (zh) 2018-07-13
TW201643185A (zh) 2016-12-16
DOP2017000246A (es) 2018-01-31
JP2021035951A (ja) 2021-03-04
SG11201708441RA (en) 2017-11-29
US20180111980A1 (en) 2018-04-26
ES2884267T3 (es) 2021-12-10
PH12017501914A1 (en) 2018-03-05
CA2983276A1 (fr) 2016-10-27
KR20170138558A (ko) 2017-12-15
AU2016252008B2 (en) 2019-06-13
JP7465378B2 (ja) 2024-04-10
CO2017011583A2 (es) 2018-04-19
EP3985020A1 (fr) 2022-04-20
US10407490B2 (en) 2019-09-10
MX2017013687A (es) 2018-07-06
BR112017022790A2 (pt) 2018-07-17
EP3286212A1 (fr) 2018-02-28
EP3286212B1 (fr) 2021-06-02
CN107922474A (zh) 2018-04-17
CR20170482A (es) 2018-03-07
AU2019226255A1 (en) 2019-09-26
JP2023055875A (ja) 2023-04-18
UY36650A (es) 2016-11-30
EA201792269A1 (ru) 2018-04-30
AU2016252008A1 (en) 2017-11-09
EA035332B1 (ru) 2020-05-28
US20190359688A1 (en) 2019-11-28
IL255122A0 (en) 2017-12-31
JP6894846B2 (ja) 2021-06-30

Similar Documents

Publication Publication Date Title
DK3292141T3 (da) Fusionsproteiner
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK4089113T3 (da) Polypeptider
DK3197453T3 (da) Kimært protein
DK3365563T3 (da) Forbindelseskomponent
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3362444T3 (da) Forbindelser
MA41943A (fr) Polypeptides ciblant une fusion du vih
FI20155191A (fi) Nivel
BR112016029235A2 (pt) Polipeptídeos de fusão relacionados com ômega- hidroxilase com propriedades aprimoradas
DK3126521T3 (da) HNF4G-RSPO2-fusionsgen
FR3021224B1 (fr) Phytomedicament pour le vih
DK3331885T3 (da) Forbindelser
DK3310756T3 (da) Thromboxanreceptorantagonister
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
ES1202236Y (es) Bombona
ITUA20162057A1 (it) Natante
BR112017003965A2 (pt) polipeptídeos vip3 modificados
DK3302527T3 (da) Manipuleret CCL20-låst-dimerpolypeptid
ITUA20162867A1 (it) Interruttore differenziale
ES2775740T8 (es) Péptidos
UA33793S (uk) Вимикач
DE112016001702A5 (de) Gelenkanordnung
ES1153858Y (es) Antorcha hidroneumatica
UA33641S (uk) Вимикач